Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
EsoGuard demonstrated unprecedented early precancer detection, including 89% sensitivity at detecting short segment early preca...
Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.5 price target.
Cantor Fitzgerald analyst Ross Osborn maintains Lucid Diagnostics (NASDAQ:LUCD) with a Overweight and lowers the price targe...
Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.5 price target.
Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0...
Lucid Diagnostics had cash and cash equivalents of $18.9 million as of December 31, 2023, compared to $22.5 million as of Decem...
